Početna › Multipli mijelom › Indiana
Kliničke studije za Multipli mijelom u državi Indiana
19 studija za Multipli mijelom traži sudionike na lokacijama u državi Indiana.
Gradovi u državi Indiana
Službeni tekst studije (engleski)
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Franciscan Health, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07518186A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Indiana University, Indianapolis
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05201781A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Genesis Medical Research, Dyer
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT07477587A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- Fort Wayne Medical Oncology And Hematology /ID# 278141, Fort Wayne
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Community Health Network (The University of Texas MD Anderson Cancer Center), Indianapolis
U tijeku regrutacijaFaza 2
Od 12 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264Collection of Tissue Samples for Cancer Research
- Indiana University - Purdue, Indianapolis
U tijeku regrutacijaOpažajna studija
2 Months · Oba spola · Ažurirano 16. ruj 2026. · NCT00900198MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
- Community Health Network, Inc., Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 24. kol 2026. · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- IU Health North Hospital, Carmel
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- IU Health Methodist Hospital, Indianapolis
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04566328A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Indiana University, Indianapolis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 12. kol 2026. · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Indiana University Health, Indianapolis
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. kol 2026. · NCT07284758A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Fort Wayne Medical Oncology And Hematology /ID# 268179, Fort Wayne
- Franciscan St. Francis Health /ID# 280928, Indianapolis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Indiana University Health Simon Cancer Center, Indianapolis
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. srp 2026. · NCT05137054Integrated Cancer Repository for Cancer Research
- Parkview Research Center, Fort Wayne
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Community Health Network, Indianapolis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. lip 2026. · NCT04068597Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- IU Health North Hospital, Carmel
- Northwest Cancer Center - Main Campus, Crown Point
- Northwest Oncology LLC, Dyer
- i još 8
U tijeku regrutacijaFaza 3
Sve dobne skupine · Oba spola · Ažurirano 10. lip 2026. · NCT05561387cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Floyd, New Albany
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 godina i više · Oba spola · Ažurirano 20. sij 2026. · NCT05366881The Indiana Myeloma Registry
- Indiana University Simon Cancer Center, Indianapolis
U tijeku regrutacijaOpažajna studija
Od 18 godina i više · Oba spola · Ažurirano 10. stu 2025. · NCT03616483Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.